Several substances have been shown to affect hepatic heme synthesis in the rat liver. Phenobarbital and the polycyclic hydrocarbon, 3,4-benzpyrene, produce an induction of aminolevulinic acid synthetase (ALAS), the enzyme mediating the first step in heme synthesis. This is followed sequentially by increased incorporation of glycine into microsomal heme, increased microsomal protoheme, cytochrome P-450, and increases in activity of certain microsomal mixed function oxidate reactions. Microsomal cytochrome b5 is not altered during such events. 3-amino-1,2,4-triazole inhibits increases in hepatic heme synthesis and drug oxidations produced by phenobarbital and 3,4-benzyprene, but has no effect on ALAS changes or cytochrome b5. Ferrochelatase, an enzyme mediating the last step in heme synthesis, is also increased by phenobarbital treatment. This enzyme was shown to be inhibited by lead and prior administration to the animal of 3,5-diethoxycarbonyl-2,4,6-trimethylpyridine (DDC). DDC also induces ALAS activity. The combined increase in ALAS activity and inhibition of ferrochelatase by DDC could account for the profound porphyria produced by this agent. 
Several substances have been shown to affect hepatic heme synthesis in the rat liver. Phenobarbital and the polycyclic hydrocarbon, 3,4-benzpyrene, produce an induction of aminolevulinic acid synthetase (ALAS), the enzyme mediating the first step in heme synthesis. This is followed sequentially by increased incorporation of glycine into microsomal heme, increased microsomal protoheme, cytochrome P-450, and increases in activity of certain microsomal mixed function oxidate reactions. Microsomal cytochrome b5 is not altered during such events. 3-amino-1,2,4-triazole inhibits increases in hepatic heme synthesis and drug oxidations produced by phenobarbital and 3,4-benzyprene, but has no effect on ALAS changes or cytochrome b5. Ferrochelatase, an enzyme mediating the last step in heme synthesis, is also increased by phenobarbital treatment. This enzyme was shown to be inhibited by lead and prior administration to the animal of 3,5-diethoxycarbonyl-2,4,6-trimethylpyridine (DDC). DDC also induces ALAS activity. The combined increase in ALAS activity and inhibition of ferrochelatase by DDC could account for the profound porphyria produced by this agent. OF ANIMALS WITH CERTAIN DRUGS, such as phenobarbital and carcinogens, such as 3,4-benzpyrene, results in the enhancement of a variety of hepatic microsomal 0xidations.l Stimulation of these oxidations appears to depend, in part, on increases in microsomal cytochrome P-450."," Recently, evidence has been presented which demonstrates that many agents, including phenobarbital and 3,4-benzpyrene, are capable of inducing hepatic S-aminolevulinic acid (ALA) synthetase,A-7 the proposed initial and rate-limiting enzyme in the hepatic heme biosynthetic pathway,ss" which could lead to an increased rate of synthesis of hepatic heme and which, in turn, might result in the increase of cytochrome P-450 and, in certain cases, the stimulation of certain hepatic microsomal drug oxidations. Previously, we have demonstrated that enhanced heme synthesis is essential for the induction of cytochrome P-450 and the stimulation of certain hepatic microsomal drug oxidations.i*10
The present studies demonstrate the relationship between the stimulatory effects of phenobarbital and 3,4-benzpyrene on hepatic heme synthesis, cytochrome P-450, and ethylmorphine N-demethylation. Also, the effects of pheno- injections of either phenobarbital (PB) (40 mg./Kg.) or 3,4-benzpyrene (BP) (20 mg./Kg.) at the times indicated by the arrows. Control animals received an equal volume of 0.9% NaCl or corn oil. Animals were sacrificed at the time indicated, and the activity of ALA synthetase was determined in hepatic homogenates as described by Baron and Tephly.** Each point represents the mean of at least three experiments, and the brackets represent the standard error of the mean. The average control value was 16.0 mpmoles of ALA formed/Gm. liver/hr. All points were significantly (P < 0.05) increased over control values, except the value obtained 2 hours after the initial administration of 3,4-benzpyrene.
barbital administration on hepatic mitochondrial ferrochelatase, the catalyst for the last step in heme synthesis, is revealed.
RESULTS AND DISCUSSION

Eflects of Phenobarbital and 3,4-Benzpyrene Treatments on Activity of Hepatic &Aminolevulinic Acid Synthetase
A single injection of either phenobarbital or 3,4-benzpyrene ( Fig. 1) resulted in a rapid marked increase in the activity of hepatic ALA synthetase. To study the relationship between the stimulation of hepatic ALA synthetase activity and the enhancement of hepatic heme synthesis produced by both phenobarbital and 3,4_benzpyrene, the incorporation of a 30-,&i pulse-dose of glycine-2-14C into hepatic microsomal heme was employed as an index of hepatic heme synthesis in vivo (Fig. 2) . The amount of radioactivity incorporated into microsomal heme per milligram of microsomal protein increased after the onset of treatment with either agent, with maximum stimulation occurring after approximately 48 hours. The profile then shows a return toward control values, as was seen with ALA synthetase (Fig. 1) . Furthermore, in agreement with the effects of these agents on the activity of hepatic ALA synthetase, the enhancement of hepatic heme synthesis in vivo observed after treatment with 3,4-benzpyrene was approximately 50 per cent of that observed after the administration of phenobarbital. Treatment of rats with either phenobarbital or 3,4-benzpyrene resulted in an increase in the hepatic microsomal content of protoheme, as seen in Fig. 3 . The amount of microsomal protoheme per milligram of microsomal protein and per gram of liver is significantly increased (P < 0.05) 8 hours after phenobarbital administration and 12 hours after the administration of 3,4-benzpyrene, and these values remained elevated during the remainder of the study, increasing to a maximum 72 to 96 hours after the onset of treatment with either agent. However, these values also decline toward control values after a suitable period of time. In agreement with the effects of these agents on the activity of hepatic ALA synthetase and hepatic heme synthesis, increases in the hepatic microsomal content of protoheme produced by 3,4-benzpyrene was approximately 50 per cent of that observed after phenobarbital treatment.
Eflects of Phenobarbital and 3,4-Benzpyrene Treatments on Hepatic Microsomal Cytochromes
The effects of phenobarbital and 3,4-benzpyrene treatments on the content of cytochrome P-450 in hepatic microsomes are summarized in hepatic microsomes increases until, about 96 hours after the onset of treatment with either agent, a maximum is reached. However, between 96 and 120 hours, the levels of cytochrome P-450 begin to fall toward control values, although, after 120 hours of treatment, cytochrome P-450 levels were increased approximately threefold by phenobarbital and about twofold by 3,4-benzpyrene. Increasing the doses of phenobarbital and 3,4-benzpyrene during the last 72 hours of the study did not prevent cytochrome P-450 levels from declining after maximum stimulation was achieved. The observation that the 3,4-benzpyreneinduced increase in cytochrome P-450 levels was about 50 per cent of that produced by phenobarbital agrees with the results seen with these agents on hepatic ALA synthetase activity, hepatic heme synthesis, and the hepatic microsomal protoheme content.
In spite of the stimulatory effect of phenobarbital and 3,Cbenzpyrene on microsomal content of cytochrome P-450, the levels of cytochrome b5 in hepatic microsomes were unaffected during the first 48 hours of treatment, although, as seen in Fig. 5 , the amount of cytochrome b5 per milligram of microsomal protein did increase (P < 0.05) between 96 and 120 hours after the onset of treatment with either agent.
These results indicate that enhanced formation of ALA is followed sequentially by an increased hepatic capacity to synthesize heme in vivo, increases in microsomal P-450 and protoheme. However, no substantial effects on cytochrome bg levels were produced during these events. 
Effect of Aminotriazole on Hepatic Microsomul Heme Synthesis and on Stimulation of Hepatic Microsomal Heme Synthesis by Phenobarbital
If the synthesis and stimulation of synthesis of microsomal P-450 is dependent on heme synthesis, then an inhibitor of heme synthesis ought to be capable of inhibiting P-450 synthesis and the induction of P-450 synthesis produced by phenobarbital and other inducers. A well-known inhibitor of hepatic catalase activity, 3-amino-1,2,4-triazole (AT) has been used in our laboratory as an inhibitor of methanol metabolism in the rat.13J4 This substance has been shown to inhibit Caminolevulinic acid dehydratase activity,15 the catalyst for the second step in heme synthesis, that responsible for the conversion of ALA to porphobilinogen. We showed that AT was an inhibitor of ALA dehydratase in vitrol" but not a very potent one. However, in vivo, AT was a fairly effective inhibitor of the incorporation of ALA-l"C into microsomal heme. This is seen in Table 1 . AT produced at 40 per cent inhibition of the rate of incorporation of ALA into microsomal heme and phenobarbital had no effect on the incorporation of ALA into microsomal heme. These results were expected because, by studying ALA incorporation, we are probably bypassing the ratelimiting step in heme synthesis, and this is where phenobarbital is exerting its major stimulatory effect under the conditions of this experiment. Table 2 shows that AT also inhibits "QFe incorporation into microsomes and into microsomal heme. Phenobarbital produced a stimulation of "gFe incorporation, which was reversed by simultaneous administration of AT. Therefore, AT is capable of inhibiting hepatic heme synthesis and reverses the stimulation of the heme synthesis produced by phenobarbital.
The effect of AT on the induction of hepatic microsomal P-450 by phenobarbital is shown in Fig. 6 . The expected stimulatory effect of phenobarbital is shown as well as the effect of AT alone. Treatment with AT alone produced a minimum decrease in P-450 levels of nearly 50 per cent approximately 16 hours after administration, and the simultaneous administration of AT with phenobarbital effectively reduced the induction of P-450 produced by phenobarbital. We feel that this points out the dependence of P-450 synthesis and the dependence of the phenobarbital stimulation of P-450 synthesis on heme synthesis. AT had no effect on the concentration of microsomal cytochrome b, in microsomes which was not unexpected since phenobarbital had no effect on b6 synthesis (Fig. 5) . The pattern of ethylmorphine N-demethylation (Fig. 7 ) resembles that seen with P-450, namely, a 40 per cent decrease in ethylmorphine demethylation in hepatic microsomes with AT treatment alone, the stimulation by phenobarbital administration, and the reversal of phenobarbital induction by AT. This suggests that under certain conditions ethylmorphine metabolism is dependent upon P-450 levels. However, this is not always the case, as has been shown previously. 1° Several experiments show that AT does not exert its effect through inhibition of protein synthesis. Amino acid incorporation into microsomal protein is not altered by ATlo and the stimulation of a microsomal protein, NADPH- HOUI!OW TRE;:ME"T 48 cytochrome c reductase, by phenobarbital is not affected by AT under conditions that did interrupt the effect of phenobarbital on P-450 (Fig. 8) . Furthermore, it has been shown by Raisfeld et al. l6 that AT had no effect on the increases in microsomal phospholipid or proliferation of smooth membranes produced by phenobarbital. Also, AT has no effect on the induction of ALA synthetase produced by phenobarbital administration.
Studies on Hepatic Mitochondrial Ferrochelatase
The last step in heme synthesis, that mediated by ferrochelatase, occurs in the mitochondria and is closely associated with ALA synthetase. Because of the striking effects of phenobarbital and other substances on ALA synthetase, we have recently turned our attention to an understanding of this enzyme and its properties. Our studies were first directed at development of an assay for this enzyme and, since others l7 had employed cobalt as substrate instead of iron, we began our work by studying the incorporation of cobalt into protoporphyrin IX under aerobic conditions. Figure 9 shows the typical spectrum that develops Mitochondria were prepared from livers of 50 gram, male, SpragueDawley rats. Reactions were carried out aerobically at 37" C and they contained 50 PM protoporphyrin IX, 50 aM cobalt chloride, 0.1% Tween 80, mitochondria, 3 mg. of protein/ml. reaction mixture and glycine buffer, 0.1 M, pH 7.8. The spectra were measured on a Shimadzu split-beam spectrophotometer.
Blank reactions had cobalt added just prior to recording and reactions were linear to 75 minutes under these conditions. effect of preincubation of mitochondria at 60" C on the activity of cobalt and ferrochelatase activity. Ferrochelatase activity was determined by the method of Porra and Jones18 except that GSH was omitted from reaction mixtures and glycine buffer was employed. Cobalt chelatase activity was determined as in Fig. 9 .
PREINCUBATION (MIN)
when cobalt and protoporphyrin IX are reacted with hepatic mitochondria. Mitochondria were prepared according to the method of Jones and Jones,17 with one exception. We found that Tris buffer produced a spectrum when combined with cobalt and, therefore, we employed glycine buffer for our preparation. When either cobalt, protoporphyrin IX, or mitochondria were omitted from the reaction mixtures, no spectra were obtained. Furthermore, the formation of the absorbance band at about 430 rnp was dependent on time and protein concentration. This was our routine assay for the incorporation of cobalt into protoporphyrin IX. In addition to this assay, we used the method of Porra and Jonesls to measure the formation of heme from ferrous ion and protoporphyrin IX under anaerobic conditions. Reduced glutathione was omitted from the reaction mixture.
The distribution of cobalt and ferrochelatase has been reported to be similar,18 and we have also conducted several experiments that pointed to a single enzyme mediating both reactions. For example, cobalt and ferrochelatase activity yield similar thermolability to heat (Fig. 10) . It has been reported by Mazanowska et al.ls that ether stimulates ferrochelatase activity. It can be seen in Fig. 11 that ether stimulates both cobalt and ferrochelatase activity, but not to the same degree. This was the first indication to us that there might be a difference between these activities. Table 3 shows that when copper or nickel chloride was employed in reaction mixtures, no effect was obtained on the cobalt chelatase activity, but a profound inhibition of ferrochelatase activity was observed. Ferric ion has no effect on either system and EDTA inhibits both systems to about the same extent. Mercury and silver salts were not effective inhibitors of either system and parahydroxymercuribenzoate was almost completely ineffective as an inhibitor. Lead was shown to be a potent inhibitor of ferrochelatase activity, which was expected since profound coproporphyrinuria is found in lead poisoning. It has not been possible to examine the effect of lead on cobalt chelatase activity at this time. However, these data suggest that cobalt and ferrochelatase may be different enzymes. effect of diethylether on cobalt and ferrochelatase activity in rat liver mitochondria. Cobalt chelatase was assessed as described in Fig. 9 and ferrochelatase activity was measured as described in Fig. 10 . Diethylether (peroxide-free), 50 ~1.. was added to reaction mixtures and activity obtained was compared to that found in the absence of ether (100% activity).
Co-Method
Fe -Method Figure 12 shows a distribution of cobalt and ferrochelatase activity in various organs of the rat with activity in the liver represented as 100 per cent. These data clearly show that the activity of cobalt chelatase in the heart is very low when compared to the liver, but that ferrochelatase activity is even higher in the heart than in the liver. The dissimilarities in the ratios of ferrochelatase and cobalt chelatase activities in the various rat organs indicated further that different enzymes are involved.
After these observations were made we studied the effect of phenobarbital administration on ferrochelatase activity (Fig. 13 ). Many months before we had observed that phenobarbital administration had no effect on the cobalt chelatase activity in the rat liver. However, when ferrochelatase activity was studied using the pyridine hemochrome formation as a measure of the activity of this enzyme, a substantial increase in mitochondrial activity was observed. Recently, we have shown that this effect can be prevented with simultaneous administration of cycloheximide. Therefore, we view this as a true induction. -Distribution of cobalt and ferrochelatase activity in mitochondria obtained from various organs of the rat. Mitochondria were assayed for cobalt and ferrochelatase activity and compared to that found in hepatic mitochondria of untreated rats. Activity in hepatic mitochondria was considered as 100%.
Addition of phenobarbital to reaction mixtures has no effect on the enzyme. DDC (3,5-diethoxycarbonyl-2,4,6_trimethylpyridine) is a well-known porphyria-producing agent which is a potent inducer of ALA synthetase.s It was found that after injection of rats with this agent (300 mg./Kg.) there was no effect on cobalt chelatase activity, but a substantial inhibition of ferrochelatase activity was produced. This is shown in Fig. 14 with the effect of phenobarbital obtained 24 hours after the start of treatment. Onisawa and LabbezO had reported this effect previously, but we feel that this observation is an essential one in explaining the porphyria produced by DDC. Not only must one have an induction of ALA synthetase, but the development of a rate-limiting step further on in the heme synthetic pathway for the production of a porphyria as well. Male, SpragueDawley rats (50 Gm.) were administered phenobarbital sodium (60 mg./Kg.) at the arrows (solid line) or saline (dashed line). Activity was determined by the pyridine hemochrome assay (Fig. 10) . Each point represents the mean value k S.E.M. from 4 animals. No effect of phenobarbital on cobalt chelatase activity was observed. All animals were fasted for 24 hours prior to sacrifice but water was allowed ad libitum. or dimethylsulfoxide (DDC). Dimethylsulfoxide had no effect when compared to saline controls. The degree of inhibition produced by DDC treatment is dependent upon the time periods during which measurements are taken. These data represent the difference in rate of formation of heme during a period of linear product formation. However, no activity was obtained in mitochondria prepared from DDC-treated rats during the first 10 minutes of incubation.
These studies document the induction of rat hepatic mitochondrial ferrochelatase by the chronic treatment of rats with phenobarbital, which was observed only when pyridine hemochrome formation was measured and not when the formation of the cobalt protoporphyrin IX complex was examined. Also, there is an insensitivity of cobalt chelatase activity to copper and nickel, metals that inhibited pyridine hemochrome formation. One likely explanation for this dissociation is that a different enzyme mediates cobalt complexation. However, one cannot exclude the possibility that a metal carrier system for iron is being affected with phenobarbital treatment and with certain metals. but that no carrier or a different carrier is required for cobalt transport to the enzyme.
It is interesting to note that the temporal response of ferrochelatase activity after phenobarbital administration is quite different from that observed with ALA synthetase activity. One may suggest that the ALA synthetase activity and ferrochelatase are reciprocally related and that increases in ferrochelatase activity are promoted through increased flux of porphyrin substrate brought about by increased ALA synthetase activity. In turn, the increased heme formed by these events may be responsible for the decreases in ALA synthetase activity upon prolonged phenobarbital administration. It has been suggested by Granick and his colleagues Q*21~22 that heme participates in the regulation of the synthesis of ALA synthetase on the basis of a feed-back repression. Scholnick et al.":' have described the direct inhibition of soluble ALA synthetase by heme, which could account for another manner of control of heme synthesis in the mammal. It is also possible that the synthesis of ALA synthetase and ferrochelatase are independent of each other.
